Neutralase heparinase I enzyme: IBT discontinued its suspended Phase III trial

The discontinued trial was using a dose of 7 µg/kg Neutralase, which achieved the target reduction in activated clotting time (ACT) but did not reverse heparin sufficiently to prevent blood loss, leading to an increased rate of bleeding in the Neutralase group compared to the protamine control group. Neutralase-treated patients did show fewer drops in blood pressure and fewer increases in pulmonary artery pressure than those on protamine. ...